Authors:

Sathveka Sembian

Date Created:

Not specified

Course Title:

Professor:

Not specified

About Paper:

Cervical cancer remains the fourth most leading cancer in women on a global scale. At least 95% of cervical cancer develops from human papillomavirus (HPV) infection. HPV DNA tests are used as routine screening for the early detection of high-risk HPV (hrHPV) strains (eg, HPV16). Despite recent advances in screening, Hispanic women present with a 40% higher rate of cervical cancer diagnosis compared to non-Hispanic whites. Such disparities continue at the state-level, as Indiana ranks second in the nation for the highest cervical cancer incidence rate for Hispanic women (12.2 per 100,000 women), as compared to 9.7 for the U.S (as of 2019). Such disproportionate burden may correlate with lack of transportation, limited knowledge and awareness, and several other sociocultural barriers. The development of a rapid and accurate in-clinic HPV self-sampling test may alleviate such barriers and improve screening uptake. To explore stakeholders' perspectives, interview and survey data were collected from Indiana community members and clinicians in late 2021-22. Preliminary results reveal that lack of self-efficacy emerged as a barrier, whereas "increased comfort" and "saves time" emerged as facilitators in the context of HPV self-sampling at the clinic. Additionally, a variety of self-collection methods (including brushes, swabs, and cell lysis reagents) will be evaluated in their ability to reliably collect samples for DNA detection. Thus far, saponin and TritonX100 are demonstrating efficacy in lysing cells to free the virus DNA, without interfering with downstream DNA detection.

Source:

Purdue University / 2023

Topics:

No topics listed

Co-authors:

Sathveka Sembian